Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Dec 18, 2024; 15(12): 1155-1163
Published online Dec 18, 2024. doi: 10.5312/wjo.v15.i12.1155
Published online Dec 18, 2024. doi: 10.5312/wjo.v15.i12.1155
Prognostic factors in patients with bone metastasis of lung cancer after immune checkpoint inhibitors: A retrospective study
Yuki Ishibashi, Hiroshi Kobayashi, Toshihiko Ando, Kouichi Okajima, Takahiro Oki, Yusuke Tsuda, Sakae Tanaka, Department of Orthopaedic Surgery, The University of Tokyo, Bunkyo-ku 113-8655, Tokyo, Japan
Yusuke Shinoda, Department of Rehabilitation, The Saitama Medical University, Morohongo 350-0495, Saitama, Japan
Ryoko Sawada, Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Hyogo, Japan
Author contributions: Ishibashi Y and Kobayashi H wrote the manuscript and reviewed the relevant literature; Okajima K, Oki T, Tsuda Y, Shinoda Y, Sawada R, and Tanaka S contributed to the conception and design of the study and critically revised the manuscript. All authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the University of Tokyo Hospital’s institutional review board (approval number: 11019). All study procedures followed the ethical standards of the 1975 Helsinki Declaration (as revised in 2000) and national law.
Informed consent statement: As we use a blanket consent system, no consent form was provided for this study.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hiroshi Kobayashi, PhD, Department of Orthopaedic Surgery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku 113-8655, Tokyo, Japan.
Received: August 21, 2024
Revised: October 14, 2024
Accepted: November 8, 2024
Published online: December 18, 2024
Processing time: 118 Days and 2.2 Hours
Revised: October 14, 2024
Accepted: November 8, 2024
Published online: December 18, 2024
Processing time: 118 Days and 2.2 Hours
Core Tip
Core Tip: Use of Immune checkpoint inhibitors after bone metastasis diagnosis may be a favorable prognostic factor in patients with bone metastases from gene mutation-negative non-small cell lung cancer.